Photo Credit: by Felicity Tai, Pexels.com
In 2025, the fight against high “bad” cholesterol (LDL) has gained a potent new arsenal. Beyond high-intensity statins, injectable PCSK9 inhibitors, like evolocumab (Repatha) and alirocumab (Praluent), and the siRNA therapy inclisiran (Leqvio), can lower LDL by up to 59% and cut major adverse cardiovascular events by 15%, delivering unprecedented reductions in heart attack and stroke risk. Backed by landmark clinical trials and now more accessible than ever, these treatments are reshaping how clinicians and patients approach heart health. This deep dive explains the science in plain language, outlines why PCSK9 inhibitors matter, and shows how to integrate them into your treatment plan.
Understanding Cholesterol: HDL vs. LDL, Good vs. Bad
Cholesterol is a waxy, fat-like molecule our bodies need for vital functions: building cell membranes, producing hormones (such as estrogen and testosterone), and making bile acids to digest fats. We get cholesterol in two ways: our liver manufactures it, and we absorb it from animal-based foods like eggs, meat, and dairy.
Because cholesterol can’t travel alone in the bloodstream, it hitches a ride on lipoproteins, microscopic particles in your blood that carry fats. The two you’ll hear most about are:
1. Low-Density Lipoprotein (LDL)
This is often said to be the “bad” cholesterol. High LDL levels mean more cholesterol is delivered to tissues, including your artery walls. Excess LDL penetrates the inner lining of arteries, creating fatty streaks that develop into plaque. Over the years, plaque buildup (atherosclerosis) narrows and stiffens arteries, raising the risk of coronary artery disease, heart attacks, stroke, and peripheral artery disease.
Most adults should aim for a range of < 100 mg/dL; however, those with cardiovascular disease or diabetes may need to aim for lower numbers.
2. High-Density Lipoprotein (HDL)
This type of lipoprotein is thought of as the “good” cholesterol. High-density lipoprotein scavenges excess cholesterol from tissues and plaques, transporting it back to the liver for disposal. Higher HDL is linked with lower cardiovascular risk.
A desirable target for HDL is ≥ 60 mg/dL. If the HDL is < 40 mg/dL for men or < 50 mg/dL for women, it can increase the of cardiovascular disease.
To learn more about blood cholesterol, see here.
Reduce Bad Cholesterol
Lifestyle modifications like a heart-healthy diet, regular exercise, weight control, and smoking cessation are the first-line options when trying to reduce your LDL. However, medication may become necessary if:
• Your LDL remains above your target range despite lifestyle changes.
• You have very high baseline LDL (≥190 mg/dL), suggesting genetic high cholesterol (hypercholesterolemia), where early drug therapy is critical.
• You have cardiovascular disease or diabetes, with an LDL >70 mg/dL on statins.
For more on the management of blood cholesterol, see here.
Why PCSK9 Inhibitors Stand Out
Medications known as statins reduce cholesterol production in the liver, lowering LDL by about 50-60% in high-intensity doses. But many high-risk patients still fall short of optimal LDL levels. A different type of medication known as a PCSK9 inhibitor offers a complementary approach by unleashing the liver’s natural capacity to clear LDL.
Below are the key advantages of PCSK9 inhibitors:
• Substantial LDL reduction (a 50-60% drop when used with a statin): After statins have done their part, PCSK9 inhibitors further lower LDL to levels once thought unreachable. By blocking or reducing PCSK9, these drugs free up LDL receptors on functional liver cells (hepatocytes), enabling the liver to remove twice as much LDL from the bloodstream. Real-world data shows LDL reductions of up to 60%, even in patients on the highest dose of statins they could tolerate. (See here and here.)
• Proven major adverse cardiovascular events reduction (15-20% when compared to those on statins alone): It’s one thing to move lab numbers; it’s another to prevent heart attacks and strokes. Landmark trials report a 15% relative reduction in major adverse cardiovascular events (MACE) with evolocumab and a similar trend in the alirocumab study. This translates into real-world lives saved and hospitalizations averted.
• Flexible dosing (biweekly to twice-yearly): Patient preferences vary, so flexible dosing can be helpful. Evolocumab (Repatha) offers 140 mg biweekly or 420 mg monthly injections, alirocumab (Praluent) can run 75-150 mg every two weeks, and inclisiran (Leqvio) requires only two doses per year after the initial loading. Such flexibility helps tailor therapy to lifestyles, whether you want consistent monthly reminders or minimal dosing appointments.
• Excellent safety profile: Because PCSK9 inhibitors work outside cholesterol-making pathways, side effects are generally mild. The most common complaint is injection-site reaction (redness or itching, for example), which resolves quickly. No liver-enzyme elevations or muscle pain occur, as is seen occasionally with statins.
• Enhanced adherence with long-acting medication: Taking medication less frequently (such as twice a year for inclisiran) simplifies life. Lower injection burden often translates into better long-term adherence. This is critical for chronic disease management.
How PCSK9 Inhibitors Work vs. Statins
When looking at a new medication type, you might want to know a little about how it works. Statins and PCSK9 inhibitors both lower LDL, but they do it in very different ways. Statins curb new cholesterol creation while PCSK9 inhibitors maximize the liver’s ability to clear existing LDL.
Here are the technical details:
• High-intensity statins inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA; a key metabolic intermediate in both cholesterol synthesis and ketone-body formation) reductase (a type of enzyme). By blocking this rate-limiting step, statins reduce cholesterol production in the liver, which upregulates LDL receptors and increases LDL clearance. This results in a 50-60% reduction in LDL.
• PCSK9 inhibitors either block PCSK9 with monoclonal antibodies that bind circulating PCSK9 and prevent it from targeting LDL receptors for destruction, or use short, double-stranded RNA (siRNA) molecules to degrade PCSK9 mRNA in hepatocytes and silence its production. This preserves LDL receptors and yields an additional 50–60% reduction in LDL when compared to statins alone.
Practical Injection Tips
You might feel intimidated if you’re injecting your medication from a prefilled syringe for the first time. However, mastering technique enhances comfort and efficacy.
Consider these injection tips to make things go smoothly, whether you’re a seasoned pro or this is your first injection:
1. Don’t always inject in the same spot. Changing injection spots can reduce potential side effects and ensure constant absorption of the medication. You can choose your abdomen (at least two inches from navel), the front of your thighs, or the back of your upper arms.
2. Make sure your syringe is room temperature. Remove the syringe from the fridge about 30 minutes before injection to reduce discomfort.
3. Clean your skin. With clean hands, swab the injection spot with isopropyl alcohol in a circular motion. Let the area fully air-dry.
4. Pinch your skin and inject. Gently pinch a fold of skin and insert the needle at 45-90 degrees. Depress the plunger steadily for over five seconds or more.
5. Hold, then withdraw the needle. Keep the syringe in place for five seconds post-injection and then withdraw and apply gentle pressure. Avoid rubbing the area.
6. Dispose of your syringe safely. Use a Food and Drug Administration (FDA)-approved puncture-resistant container for disposal. You can get one at a pharmacy, at a medical supply store, or from your healthcare provider.
For more details on using prefilled syringes, see here.
A Holistic Heart-Health Strategy
While PCSK9 inhibitors are highly effective at lowering cholesterol, they work best when combined with other risk-reduction measures.
If you’re focused on cholesterol reduction and heart health, consider these tips:
• Control your blood pressure. Aim to keep your blood pressure below 130 over 80. (You may need to use additional medication to do so.) And remember, for every 10-point drop in your top number (the “systolic” reading), you cut your risk of heart problems by about 22% and your risk of stroke by about 41%.
• Watch your blood sugar. Try to keep your A1C—a measure of your average blood sugar over the past 2-3 months—below 7%. That helps protect your blood vessels throughout the body. Studies show that for some, aiming for an A1C under 7% can cut your risk of small-vessel damage in your eyes, kidneys, and nerves by about a quarter.
• Maintain a healthy diet and don’t forget to exercise. Adopting a Mediterranean-style diet can cut your chance of heart attacks and strokes by about 37%. Adding at least 150 minutes of moderate exercise each week can further lower your cardiovascular risk by roughly 20-30%.
• Try to quit smoking. Even brief talks with telephone counseling about stopping smoking can increase your chances of success by 38%. And some who quit lower their heart attack and stroke risk by roughly 36% over two years.
• Watch your weight. Dropping just 5-10% of your body weight can often lead to noticeable improvements in your cholesterol numbers and help bring down your blood pressure.
As you can see, while medication can be a vital part of the equation when considering your health, there are many lifestyle changes that you can do at home to help.
Conclusion
Medications like PCSK9 inhibitors mark a paradigm shift in cholesterol management. With robust trials supporting their efficacy and safety, evolocumab (Repatha), alirocumab (Praluent), and inclisiran (Leqvio) empower clinicians and patients to achieve LDL levels once deemed unattainable. Their flexible dosing options, from biweekly to twice yearly, and favorable side effect profiles make them well suited for high-risk individuals whose LDL remains elevated despite statins. When integrated into a comprehensive heart-health plan including blood pressure and glucose control, lifestyle changes, and weight management, PCSK9 inhibitors can dramatically lower the risk of heart attack and stroke. As we continue to fine-tune precision medicine and patient support, these cutting-edge therapies promise to redefine cardiovascular prevention in 2025 and beyond.
Sources
1. Bittner, V. A., Schwartz, G. G., Bhatt, D. L., Chua, T., et al. (2024). Alirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after acute coronary syndrome: a report from the ODYSSEY OUTCOMES study. Journal of Clinical Lipidology, 18(4), e548–e561. https://doi.org/10.1016/j.jacl.2024.04.122
2. Critchley, J. A., & Capewell, S. (2003). Mortality risk reduction associated with smoking cessation in patients with coronary heart disease. JAMA, 290(1), 86. https://doi.org/10.1001/jama.290.1.86
3. Coppinger, C., Movahed, M. R., Azemawah, V., Peyton, L., et al. (2022). A comprehensive review of PCSK9 inhibitors. Journal of Cardiovascular Pharmacology and Therapeutics, 27. https://doi.org/10.1177/10742484221100107
4. Goodman, S. G., Steg, P. G., Poulouin, Y., Bhatt, D. L., et al. (2023). Long‐Term efficacy, safety, and tolerability of Alirocumab in 8242 patients eligible for 3 to 5 years of Placebo‐Controlled observation in the ODYSSEY OUTCOMES trial. Journal of the American Heart Association, 12(18). https://doi.org/10.1161/jaha.122.029216
5. Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., et al. (2018). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Journal of the American College of Cardiology, 73(24), e285–e350. https://doi.org/10.1016/j.jacc.2018.11.003
6. How to give yourself a subcutaneous injection using a prefilled. (2023, December 7). Memorial Sloan Kettering Cancer Center. Retrieved August 5, 2025, from https://www.mskcc.org/cancer-care/patient-education/how-give-yourself-subcutaneous-injection-using-prefilled-syringe
7. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. (1998, September 12). PubMed. https://pubmed.ncbi.nlm.nih.gov/9742976/
8. Landmesser, U., Koenig, W., Leiter, L. A., Raal, F. J., et al. (2023). Inclisiran in patients with prior myocardial infarction: A post hoc pooled analysis of the ORION-10 and ORION-11 Phase 3 randomised trials. Atherosclerosis, 386, 117354. https://doi.org/10.1016/j.atherosclerosis.2023.117354
9. Law, M. R., Morris, J. K., & Wald, N. J. (2009). Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ, 338(may19 1), b1665. https://doi.org/10.1136/bmj.b1665
10. Matkin, W., Ordóñez-Mena, J. M., & Hartmann-Boyce, J. (2019). Telephone counselling for smoking cessation. Cochrane Library, 2019(5). https://doi.org/10.1002/14651858.cd002850.pub4
11. Nocon, M., Hiemann, T., Müller-Riemenschneider, F., Thalau, F., et al. (2008). Association of physical activity with all-cause and cardiovascular mortality: a systematic review and meta-analysis. European Journal of Cardiovascular Prevention & Rehabilitation, 15(3), 239–246. https://doi.org/10.1097/hjr.0b013e3282f55e09
12. Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., et al. (2017). Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New England Journal of Medicine, 376(18), 1713–1722. https://doi.org/10.1056/nejmoa1615664
13. Sofi, F., Abbate, R., Gensini, G. F., & Casini, A. (2010). Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. American Journal of Clinical Nutrition, 92(5), 1189–1196. https://doi.org/10.3945/ajcn.2010.29673
14. Wing, R. R., Lang, W., Wadden, T. A., Safford, M., et al. (2011). Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care, 34(7), 1481–1486. https://doi.org/10.2337/dc10-2415